Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer
Interventions: DRUG: BGB-290
Sponsor: BeiGene